Table 2.

Association of Quintiles of Percent Change in eGFR Over Time and All-Cause Mortality

Quintile of eGFR Change	HR, 95% CI	P Value	HR, 95% CI	P Value	HR, 95% CI	P Value	HR, 95% CI	P Value
Change in eGFR from pre-MCS to 1 mo post-MCS	Unadjusted		Adjusted for pre-MCS eGFR		Adjusted for 1 mo eGFR		Adjusted for patient characteristics*,†
1 (<0%, any worsening)	1.96, 1.48–2.60	<0.0001	2.22, 1.68–2.95	<0.0001	1.72, 1.29–2.29	0.0002	1.63, 1.15–2.13	0.004
2 (0%–22% improvement)	1.31, 0.94–1.84	0.12	1.36, 0.97–1.90	0.08	1.25, 0.89–1.76	0.19	1.25, 0.87–1.78	0.22
3 (22%–47% improvement)	Reference group	…	…	…	…	…	…	…
4 (47%–88% improvement)	1.45, 1.07–1.96	0.02	1.36, 1.01–1.84	0.049	1.52, 1.12–2.06	0.007	1.40, 1.02–1.93	0.04
5 (>88% improvement)	2.02, 1.51–2.70	<0.0001	1.61, 1.19–2.19	0.003	2.20, 1.64–2.96	<0.0001	1.64, 1.19–2.26	0.002
Change in eGFR from 1 mo to 3 months post MCS (n=2416)	Unadjusted		Adjusted for 1 mo eGFR		Adjusted for 3 mo eGFR		Adjusted for patient characteristics*,‡
1 (>30% worsening)	2.07, 1.43–3.00	0.0001	2.34, 1.62–3.40	<0.0001	1.87, 1.28–2.71	0.001	1.74 1.17–2.58	0.006
2 (16%–30% worsening)	1.51, 1.02–2.22	0.04	1.59, 1.08–2.35	0.02	1.47, 1.00–2.17	0.05	1.36, 0.90–2.04	0.14
3 (0%–16% worsening)	Reference group	…	…	…	…	…	…	…
4 (0.1%–17% improvement)	1.28, 0.87–1.87	0.21	1.21, 0.82–1.77	0.33	1.34, 0.91–1.96	0.14	1.10, 0.72–1.65	0.66
5 (>17% improvement)	1.80, 1.24–2.61	0.002	1.42, 0.97–2.10	0.07	1.93, 1.32–2.80	0.0006	1.54, 1.03–2.30	0.03

CI indicates confidence interval; eGFR, estimated glomerular filtration rate; HR, hazards ratio; INTERMACS, Interagency Registry for Mechanically Assisted Circulatory Support; and MCS, mechanical circulatory support.

^*Adjusted for age, sex, race, diabetes mellitus, chronic lung disease, ischemic cause, New York Heart Association class, device type, device strategy (destination vs bridge to transplant), INTERMACS Profile, year of MCS implant, baseline β-blocker use, baseline angiotensin-converting enzyme inhibitor or angiotensin receptor blocker use, baseline loop diuretic use, baseline inotrope use, and dialysis requirement.

^†Adjusted for 1-mo eGFR.

^‡Adjusted for 3-mo eGFR.